Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 112,378 | 132,858 | 142,700 | 152,494 | 173,199 |
| Receivables | 2,823 | 2,427 | 4,145 | 4,512 | 2,236 |
| TOTAL | $117,553 | $139,526 | $150,613 | $157,366 | $175,854 |
| Non-Current Assets | |||||
| PPE Net | 2,572 | 2,615 | 2,387 | 2,440 | 2,073 |
| Intangibles | 3,856 | 3,881 | 3,889 | 3,866 | 3,945 |
| Other Non-Current Assets | 328 | 300 | 295 | 169 | 169 |
| TOTAL | $6,755 | $6,796 | $6,571 | $6,476 | $6,188 |
| Total Assets | $124,308 | $146,322 | $157,183 | $163,842 | $182,041 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,197 | 9,297 | 5,994 | 7,715 | 6,138 |
| TOTAL | $11,878 | $12,709 | $10,623 | $13,697 | $13,651 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2,567 | 3,411 | 4,629 | 5,982 | 7,513 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $11,878 | $12,709 | $10,623 | $13,697 | $13,651 |
| Shareholders' Equity | |||||
| Common Shares | 3,722 | 3,747 | 3,754 | 3,592 | 3,613 |
| Retained earnings | 100,125 | 123,562 | 137,166 | 141,073 | 159,681 |
| Other shareholders' equity | 8,582 | 6,305 | 5,640 | 5,480 | 5,097 |
| TOTAL | $112,429 | $133,613 | $146,560 | $150,145 | $168,391 |
| Total Liabilities And Equity | $124,308 | $146,322 | $157,183 | $163,842 | $182,041 |